Company Description
Aktis Oncology is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies.
We see a significant opportunity to broaden the cancer patient populations benefiting from targeted radiopharmaceuticals by developing next-generation technologies that expand the scope of tumor targets for which it is possible to safely deliver a powerful payload of an alpha-emitting radioisotope.
To ensure patient demand is reliably met, we are also establishing efficient end-to-end supply, with a combination of critical internal capabilities paired with established external vendors.
Through these efforts, we seek to maximize clinical utility across multiple indications in multiple tumor types, and to expand the commercial uptake of radiopharmaceuticals beyond the traditional nuclear medicine setting and into the more expansive clinical oncology setting.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Matthew Roden, PhD |
Contact Details
Address: 17 Drydock Avenue, Suite 17-401 Boston, MA 02210 United States | |
| Phone | (617) 461-4023 |
| Website | aktisoncology.com |
Stock Details
| Ticker Symbol | AKTS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2035832 |
| Employer ID | 85-2584233 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew Roden, PhD | President, Chief Executive Officer and Director |
| Kyle D. Kuvalanka | Chief Financial Officer |
| Shulamit Ron-Bigger, PhD | Chief Operating Officer |
| Paul L. Feldman, PhD | Chief Scientific Officer |
| Todd Foley, MBA | Chair of the Board of Directors |
| Ken Herrmann, MD | Director |
| Helen S. Kim, MBA | Director |
| Andrew Levin, MD, PhD | Director |
| Oleg Nodelman | Director |
| Lloyd M. Segal, MBA | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 14, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 22, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Dec 13, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Nov 22, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Oct 11, 2024 | DRS | [Cover] Draft Registration Statement |
| Oct 2, 2024 | D | Notice of Exempt Offering of Securities |